Michel D Ferrari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2246863/publications.pdf

Version: 2024-02-01

500 papers	41,552 citations	2795 94 h-index	3394 183 g-index
511 all docs	511 docs citations	511 times ranked	24714 citing authors

#	Article	IF	Citations
1	Familial Hemiplegic Migraine and Episodic Ataxia Type-2 Are Caused by Mutations in the Ca2+ Channel Gene CACNL1A4. Cell, 1996, 87, 543-552.	13.5	2,287
2	Migraine â€" Current Understanding and Treatment. New England Journal of Medicine, 2002, 346, 257-270.	13.9	1,692
3	European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology, 2020, 58, 1-464.	0.7	1,555
4	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	6.0	1,085
5	Coding of facial expressions of pain in the laboratory mouse. Nature Methods, 2010, 7, 447-449.	9.0	1,024
6	Oral triptans (serotonin 5-HT 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet, The, 2001, 358, 1668-1675.	6.3	927
7	Migraine as a Risk Factor for Subclinical Brain Lesions. JAMA - Journal of the American Medical Association, 2004, 291, 427.	3.8	845
8	Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet, The, 2005, 366, 371-377.	6.3	760
9	Guidelines for Controlled Trials of Drugs in Migraine: Second Edition. Cephalalgia, 2000, 20, 765-786.	1.8	615
10	A Cacna1a Knockin Migraine Mouse Model with Increased Susceptibility to Cortical Spreading Depression. Neuron, 2004, 41, 701-710.	3.8	595
11	Triptans (Serotonin, 5-HT1B/1DAgonists) in Migraine: Detailed Results and Methods of A Meta-Analysis of 53 Trials. Cephalalgia, 2002, 22, 633-658.	1.8	554
12	Treatment of Migraine Attacks with Sumatriptan. New England Journal of Medicine, 1991, 325, 316-321.	13.9	527
13	Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nature Genetics, 2016, 48, 856-866.	9.4	520
14	The prevalence and characteristics of migraine in a population-based cohort. Neurology, 1999, 53, 537-537.	1.5	488
15	Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet, The, 2008, 372, 2115-2123.	6.3	486
16	Migraine. Lancet, The, 1998, 351, 1043-1051.	6.3	449
17	Cardiovascular risk factors and migraine. Neurology, 2005, 64, 614-620.	1.5	426
18	C-terminal truncations in human 3â€²-5â€² DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nature Genetics, 2007, 39, 1068-1070.	9.4	366

#	Article	IF	Citations
19	Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nature Genetics, 2011, 43, 695-698.	9.4	355
20	Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet, The, 2018, 392, 2280-2287.	6.3	348
21	De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nature Genetics, 2012, 44, 1030-1034.	9.4	345
22	Genome-wide meta-analysis identifies new susceptibility loci for migraine. Nature Genetics, 2013, 45, 912-917.	9.4	338
23	Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nature Genetics, 2010, 42, 869-873.	9.4	332
24	Novel mutations in the Na+, K+-ATPase pump geneATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Annals of Neurology, 2003, 54, 360-366.	2.8	330
25	Ergotamine in the acute treatment of migraine: A review and European consensus. Brain, 2000, 123, 9-18.	3.7	329
26	Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain, 2005, 128, 2068-2077.	3.7	328
27	Delayed cerebral edema and fatal coma after minor head trauma: Role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine. Annals of Neurology, 2001, 49, 753-760.	2.8	318
28	Coronary Side-Effect Potential of Current and Prospective Antimigraine Drugs. Circulation, 1998, 98, 25-30.	1.6	314
29	Migraine pathophysiology: lessons from mouse models and human genetics. Lancet Neurology, The, 2015, 14, 65-80.	4.9	313
30	Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: The population-based MRI CAMERA study. Cephalalgia, 2010, 30, 129-136.	1.8	306
31	The impact of migraine on quality of life in the general population. Neurology, 2000, 55, 624-629.	1.5	300
32	Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nature Genetics, 2012, 44, 777-782.	9.4	294
33	Enhanced Excitatory Transmission at Cortical Synapses as the Basis for Facilitated Spreading Depression in CaV2.1 Knockin Migraine Mice. Neuron, 2009, 61, 762-773.	3.8	292
34	Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet, The, 2019, 394, 1030-1040.	6.3	269
35	Molecular genetics of migraine. Human Genetics, 2009, 126, 115-132.	1.8	255
36	Recording, analysis, and interpretation of spreading depolarizations in neurointensive care: Review and recommendations of the COSBID research group. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1595-1625.	2.4	255

#	Article	IF	Citations
37	Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia, 2018, 38, 815-832.	1.8	245
38	Serotonin metabolism in migraine. Neurology, 1989, 39, 1239-1239.	1.5	232
39	Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1. Journal of Clinical Investigation, 2009, 119, 99-109.	3.9	215
40	Migraine headache is not associated with cerebral or meningeal vasodilatationâ€"a 3T magnetic resonance angiography study. Brain, 2008, 131, 2192-2200.	3.7	212
41	Cerebral microbleeds in CADASIL. Neurology, 2001, 57, 1066-1070.	1.5	209
42	On Serotonin and Migraine: A Clinical and Pharmacological Review. Cephalalgia, 1993, 13, 151-165.	1.8	206
43	High cortical spreading depression susceptibility and migraineâ€associated symptoms in Ca_v2.1 S218L mice. Annals of Neurology, 2010, 67, 85-98.	2.8	206
44	Cutaneous allodynia as a predictor of migraine chronification. Brain, 2013, 136, 3489-3496.	3.7	202
45	Attack Frequency and Disease Duration as Indicators for Brain Damage in Migraine. Headache, 2008, 48, 1044-1055.	1.8	198
46	Structural Brain Changes in Migraine. JAMA - Journal of the American Medical Association, 2012, 308, 1889.	3.8	197
47	Migraine and MTHFR C677T genotype in a populationâ€based sample. Annals of Neurology, 2006, 59, 372-375.	2.8	193
48	Eletriptan in acute migraine. Neurology, 2000, 54, 156-156.	1.5	187
49	Towards a Definition of Intractable Headache for Use in Clinical Practice and Trials. Cephalalgia, 2006, 26, 1168-1170.	1.8	185
50	Gammahydroxybutyrate and Narcolepsy: A Double-Blind Placebo-Controlled Study. Sleep, 1993, 16, 216-220.	0.6	184
51	Wiping Out CGRP: Potential Cardiovascular Risks. Trends in Pharmacological Sciences, 2016, 37, 779-788.	4.0	179
52	Intranasal sumatriptan in cluster headache. Neurology, 2003, 60, 630-633.	1.5	168
53	Familial hemiplegic migraine locus on 19p13 is involved in the common forms of migraine with and without aura. Human Genetics, 1995, 96, 604-608.	1.8	167
54	Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy: MR Imaging Findings at Different Agesâ€"3rdâ€"6th Decades. Radiology, 2003, 229, 683-690.	3.6	165

#	Article	IF	Citations
55	Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet, The, 2001, 358, 1230-1234.	6.3	163
56	Systematic analysis of three FHM genes in 39 sporadic patients with hemiplegic migraine. Neurology, 2007, 69, 2170-2176.	1.5	163
57	The Prevalence of Premonitory Symptoms in Migraine: A Questionnaire Study in 461 Patients. Cephalalgia, 2006, 26, 1209-1213.	1.8	158
58	Rizatriptan vs Sumatriptan in the Acute Treatment of Migraine. Archives of Neurology, 1996, 53, 1132.	4.9	157
59	The Economic Burden of Migraine to Society. Pharmacoeconomics, 1998, 13, 667-676.	1.7	156
60	Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia, 2019, 39, 687-710.	1.8	154
61	Migraine. Nature Reviews Disease Primers, 2022, 8, 2.	18.1	154
62	Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. Cephalalgia, 2018, 38, 959-969.	1.8	153
63	Acute treatment of migraine with the selective 5-HT_{1F} receptor agonist lasmiditan â€“ A randomised proof-of-concept trial. Cephalalgia, 2010, 30, 1170-1178.	1.8	152
64	AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. Nature Communications, 2019, 10, 3094.	5.8	150
65	Trigeminal Autonomic Cephalgias Due to Structural Lesions. Archives of Neurology, 2007, 64, 25.	4.9	148
66	Migraine Mutations Increase Stroke Vulnerability by Facilitating Ischemic Depolarizations. Circulation, 2012, 125, 335-345.	1.6	148
67	Brain Stem and Cerebellar Hyperintense Lesions in Migraine. Stroke, 2006, 37, 1109-1112.	1.0	141
68	Neuroexcitatory plasma amino acids are elevated in migraine. Neurology, 1990, 40, 1582-1582.	1.5	138
69	Genetic Heterogeneity of Familial Hemiplegic Migraine. Genomics, 1994, 22, 21-26.	1.3	136
70	Variable clinical expression of mutations in the P/Q-type calcium channel gene in familial hemiplegic migraine. Neurology, 1998, 50, 1105-1111.	1.5	132
71	Iron Accumulation in Deep Brain Nuclei in Migraine: A Population-Based Magnetic Resonance Imaging Study. Cephalalgia, 2009, 29, 351-359.	1.8	132
72	Involvement of the CACNA1A gene containing region on 19p13 in migraine with and without aura. Neurology, 2001, 56, 1028-1032.	1.5	130

#	Article	IF	Citations
73	5-HT1-like receptor agonists and the pathophysiology of migraine. Trends in Pharmacological Sciences, 1989, 10, 200-204.	4.0	129
74	Hereditary Vascular Retinopathy, Cerebroretinal Vasculopathy, and Hereditary Endotheliopathy with Retinopathy, Nephropathy, and Stroke Map to a Single Locus on Chromosome 3p21.1-p21.3. American Journal of Human Genetics, 2001, 69, 447-453.	2.6	127
75	Frontal lobe structure and executive function in migraine patients. Neuroscience Letters, 2008, 440, 92-96.	1.0	127
76	Episodic Ataxia Associated With EAAT1 Mutation C186S Affecting Glutamate Reuptake. Archives of Neurology, 2009, 66, 97-101.	4.9	122
77	Features involved in the diagnostic delay of cluster headache. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1123-1125.	0.9	121
78	Sumatriptan in clinical practice. Neurology, 1996, 47, 46-51.	1.5	120
79	Enhanced Subcortical Spreading Depression in Familial Hemiplegic Migraine Type 1 Mutant Mice. Journal of Neuroscience, 2011, 31, 5755-5763.	1.7	119
80	Syncope in migraine. Neurology, 2006, 66, 1034-1037.	1.5	118
81	Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. Brain, 2016, 139, 2909-2922.	3.7	114
82	Migraine: gene mutations and functional consequences. Current Opinion in Neurology, 2007, 20, 299-305.	1.8	112
83	Clinical and experimental effects of sumatriptan in humans. Trends in Pharmacological Sciences, 1993, 14, 129-133.	4.0	111
84	Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain, 1996, 67, 375-378.	2.0	110
85	Oral Sumatriptan: Effect of a Second Dose, and Incidence and Treatment of Headache Recurrences. Cephalalgia, 1994, 14, 330-338.	1.8	109
86	Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis. Cephalalgia, 2017, 37, 49-63.	1.8	109
87	Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Annals of Neurology, 2002, 51, 369-372.	2.8	108
88	Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud's phenomenon. Brain, 1998, 121, 303-316.	3.7	107
89	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia, 2020, 40, 1026-1044.	1.8	105
90	Lacunar Infarcts Are the Main Correlate With Cognitive Dysfunction in CADASIL. Stroke, 2007, 38, 923-928.	1.0	104

#	Article	IF	Citations
91	Childhood epilepsy, familial hemiplegic migraine, cerebellar ataxia, and a new CACNA1A mutation. Neurology, 2004, 63, 1136-1137.	1.5	102
92	Interictal cortical hyperexcitability in migraine patients demonstrated with transcranial magnetic stimulation. Journal of the Neurological Sciences, 1996, 139, 106-110.	0.3	100
93	Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology, 1992, 42, 1522-1522.	1.5	99
94	Risk Factors for Headache Recurrence After Sumatriptan: A Study in 366 Migraine Patients. Cephalalgia, 1996, 16, 264-269.	1.8	99
95	Androgenic suppression of spreading depression in familial hemiplegic migraine type 1 mutant mice. Annals of Neurology, 2009, 66, 564-568.	2.8	99
96	Inhibition of the P2X7â€“PANX1 complex suppresses spreading depolarization and neuroinflammation. Brain, 2017, 140, 1643-1656.	3.7	99
97	Subcortical Lacunar Lesions: An MR Imaging Finding in Patients with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. Radiology, 2002, 224, 791-796.	3.6	97
98	Divergent sodium channel defects in familial hemiplegic migraine. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9799-9804.	3.3	97
99	European headache federation consensus on technical investigation for primary headache disorders. Journal of Headache and Pain, 2015, 17, 5.	2.5	97
100	MRI correlates of cognitive decline in CADASIL. Neurology, 2009, 72, 143-148.	1.5	92
101	Shared genetic basis for migraine and ischemic stroke. Neurology, 2015, 84, 2132-2145.	1.5	91
102	A high-density association screen of 155 ion transport genes for involvement with common migraine. Human Molecular Genetics, 2008, 17, 3318-3331.	1.4	90
103	Shared genetic factors in migraine and depression. Neurology, 2010, 74, 288-294.	1.5	90
104	The novel p.L1649Q mutation in theSCN1Aepilepsy gene is associated with familial hemiplegic migraine: genetic and functional studies. Human Mutation, 2007, 28, 522-522.	1.1	89
105	Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. Cephalalgia, 2016, 36, 148-161.	1.8	88
106	Chest Symptoms after Sumatriptan. Cephalalgia, 1996, 16, 554-559.	1.8	87
107	Meta-analysis of genome-wide association for migraine in six population-based European cohorts. European Journal of Human Genetics, 2011, 19, 901-907.	1.4	87
108	Hypoxia-Induced Acute Mountain Sickness is Associated with Intracellular Cerebral Edema: A 3 T Magnetic Resonance Imaging Study. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 198-206.	2.4	86

#	Article	IF	Citations
109	Early seizures and cerebral oedema after trivial head trauma associated with the CACNA1A S218L mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1125-1129.	0.9	86
110	Epigenetic mechanisms in migraine: a promising avenue?. BMC Medicine, 2013, 11, 26.	2.3	86
111	What is a clinically relevant change on the HIT-6 questionnaire? An estimation in a primary-care population of migraine patients. Cephalalgia, 2014, 34, 29-36.	1.8	86
112	Expanding the Phenotypic Spectrum of the CACNA1A Gene T666M Mutation. Archives of Neurology, 2003, 60, 684.	4.9	84
113	Cerebellar Ataxia by Enhanced Ca_V2.1 Currents Is Alleviated by Ca²⁺-Dependent K⁺-Channel Activators inCacna1a^{S218L}Mutant Mice. Journal of Neuroscience, 2012, 32, 15533-15546.	1.7	84
114	Mutation Analysis of the CACNA1A Calcium Channel Subunit Gene in 27 Patients With Sporadic Hemiplegic Migraine. Archives of Neurology, 2002, 59, 1016.	4.9	82
115	311C90, A new central and peripherally acting 5-HT _{1D} receptor agonist in the acute oral treatment of migraine. Neurology, 1996, 46, 522-526.	1.5	81
116	Migraine, ataxia and epilepsy: a challenging spectrum of genetically determined calcium channelopathies. European Journal of Human Genetics, 1998, 6, 297-307.	1.4	81
117	Abnormal transmitter release at neuromuscular junctions of mice carrying the tottering alpha1A Ca2+ channel mutation. Brain, 2000, 123, 463-471.	3.7	81
118	Cortical glutamate in migraine. Brain, 2017, 140, 1859-1871.	3.7	81
119	Brainstem spreading depolarization and cortical dynamics during fatal seizures inCacna1aS218L mice. Brain, 2019, 142, 412-425.	3.7	79
120	First Mutation in the Voltage-Gated Na_v1.1 Subunit Gene SCN1A with Co-Occurring Familial Hemiplegic Migraine and Epilepsy. Cephalalgia, 2009, 29, 308-313.	1.8	77
121	5â€HT₁ receptors in migraine pathophysiology and treatment. European Journal of Neurology, 1995, 2, 5-21.	1.7	76
122	Behavioral evidence for photophobia and stress-related ipsilateral head pain in transgenic Cacna1a mutant mice. Pain, 2013, 154, 1254-1262.	2.0	76
123	Double-Blind, Placebo-Controlled, Dose-Finding Study of Rizatriptan (MK-462) in the Acute Treatment of Migraine. Cephalalgia, 1997, 17, 647-651.	1.8	74
124	TNFÎ± Levels and Macrophages Expression Reflect an Inflammatory Potential of Trigeminal Ganglia in a Mouse Model of Familial Hemiplegic Migraine. PLoS ONE, 2013, 8, e52394.	1.1	74
125	Occipital nerve stimulation in medically intractable, chronic cluster headache. The ICON study: Rationale and protocol of a randomised trial. Cephalalgia, 2013, 33, 1238-1247.	1.8	73
126	Slowing Down of Recovery as Generic Risk Marker for Acute Severity Transitions in Chronic Diseases. Critical Care Medicine, 2016, 44, 601-606.	0.4	73

#	Article	IF	Citations
127	Severe episodic neurological deficits and permanent mental retardation in a child with a novel FHM2 ATP1A2 mutation. Annals of Neurology, 2006, 59, 310-314.	2.8	72
128	Migraine in The Elderly: A Review. Cephalalgia, 2007, 27, 97-106.	1.8	72
129	Familial and Sporadic Hemiplegic Migraine: Diagnosis and Treatment. Current Treatment Options in Neurology, 2013, 15, 13-27.	0.7	72
130	Diagnostic Notch3 sequence analysis in CADASIL: Three new mutations in Dutch patients. Neurology, 1999, 52, 1913-1913.	1.5	72
131	Are Migraineurs at Increased Risk of Adverse Drug Responses?: A Meta-Analytic Comparison of Topiramate-Related Adverse Drug Reactions in Epilepsy and Migraine. Clinical Pharmacology and Therapeutics, 2009, 85, 283-288.	2.3	71
132	Familial Hemiplegic Migraine: A Clinical Comparison of Families Linked and Unlinked to Chromosome 19. Cephalalgia, 1996, 16, 153-155.	1.8	70
133	Cerebral Hemodynamics and White Matter Hyperintensities in CADASIL. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 599-604.	2.4	70
134	Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia, 2019, 39, 1475-1487.	1.8	69
135	Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial. Brain, 2019, 142, 1203-1214.	3.7	68
136	Neuroimaging in trigeminal autonomic cephalgias: when, how, and of what?. Current Opinion in Neurology, 2009, 22, 247-253.	1.8	67
137	Is Familial Hemiplegic Migraine a Hereditary form of Basilar Migraine?. Cephalalgia, 1995, 15, 477-481.	1.8	66
138	Optogenetic induction of cortical spreading depression in anesthetized and freely behaving mice. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1641-1655.	2.4	66
139	Acetazolamide treatment for migraine aura status. Neurology, 2000, 55, 1588-1589.	1.5	65
140	Antiâ€migraine Calcitonin Geneâ€"Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice. Annals of Neurology, 2020, 88, 771-784.	2.8	64
141	Interictal cortical excitability to magnetic stimulation in familial hemiplegic migraine. Neurology, 1997, 48, 1462-1464.	1.5	63
142	From migraine genes to mechanisms. Pain, 2015, 156, S64-S74.	2.0	63
143	Common Variant Burden Contributes to the Familial Aggregation of Migraine in 1,589 Families. Neuron, 2018, 98, 743-753.e4.	3.8	63
144	Cerebral Blood Flow During Migraine Attacks Without Aura and Effect of Sumatriptan. Archives of Neurology, 1995, 52, 135-139.	4.9	62

#	Article	IF	Citations
145	Normobaric Hypoxia and Nitroglycerin as Trigger Factors for Migraine. Cephalalgia, 2006, 26, 816-819.	1.8	62
146	Migraine and Genetic and Acquired Vasculopathies. Cephalalgia, 2009, 29, 1006-1017.	1.8	61
147	Genetic analysis for a shared biological basis between migraine and coronary artery disease. Neurology: Genetics, 2015, 1, e10.	0.9	61
148	5-HT1B Receptor Polymorphism and Clinical Response to Sumatriptan. Headache, 1998, 38, 288-291.	1.8	60
149	Evaluation of diagnostic NOTCH3 immunostaining in CADASIL. Acta Neuropathologica, 2003, 106, 107-111.	3.9	60
150	Genetic Models of Migraine. Archives of Neurology, 2007, 64, 643.	4.9	60
151	Chronotypes and circadian timing in migraine. Cephalalgia, 2018, 38, 617-625.	1.8	60
152	The hypothalamus in episodic brain disorders. Lancet Neurology, The, 2002, 1, 437-444.	4.9	59
153	Familial Hemiplegic Migraine Ca_V2.1 Channel Mutation R192Q Enhances ATP-gated P2X₃ Receptor Activity of Mouse Sensory Ganglion Neurons Mediating Trigeminal Pain. Molecular Pain, 2010, 6, 1744-8069-6-48.	1.0	59
154	Clinical spectrum of hemiplegic migraine and chances of finding a pathogenic mutation. Neurology, 2018, 90, e575-e582.	1.5	59
155	P/Q-type Ca2+ channel defects in migraine, ataxia and epilepsy. Trends in Pharmacological Sciences, 1998, 19, 121-127.	4.0	58
156	CADASIL and migraine: A narrative review. Cephalalgia, 2010, 30, 1284-1289.	1.8	58
157	Validation of the web-based LUMINA questionnaire for recruiting large cohorts of migraineurs. Cephalalgia, 2011, 31, 1359-1367.	1.8	57
158	Migraine is not associated with enhanced atherosclerosis. Cephalalgia, 2013, 33, 228-235.	1.8	57
159	Two de novo mutations in the Na,K-ATPase gene ATP1A2 associated with pure familial hemiplegic migraine. European Journal of Human Genetics, 2006, 14, 555-560.	1.4	56
160	Efficacy and safety of a single intrathecal methylprednisolone bolus in chronic complex regional pain syndrome. European Journal of Pain, 2010, 14, 523-528.	1.4	54
161	Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology, 2001, 57, 1377-1383.	1.5	53
162	CACNA1A Mutation Linking Hemiplegic Migraine and Alternating Hemiplegia of Childhood. Cephalalgia, 2008, 28, 887-891.	1.8	53

#	Article	IF	Citations
163	Recent findings in headache genetics. Current Opinion in Neurology, 2004, 17, 283-288.	1.8	52
164	Blood Flow Velocity Changes in Migraine Attacks-A Transcranial Doppler Study. Cephalalgia, 1991, 11, 103-107.	1.8	51
165	Meta-Analysis of Rizatriptan Efficacy in Randomized Controlled Clinical Trials. Cephalalgia, 2001, 21, 129-136.	1.8	51
166	Myocardial Infarction in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). Medicine (United States), 2003, 82, 251-256.	0.4	51
167	GENETICS OF MIGRAINE. Neurologic Clinics, 1997, 15, 43-60.	0.8	50
168	Partial Cosegregation of Familial Hemiplegic Migraine and a Benign Familial Infantile Epileptic Syndrome. Epilepsia, 1997, 38, 915-921.	2.6	50
169	Severely impaired neuromuscular synaptic transmission causes muscle weakness in theCacna1a-mutant mouserolling Nagoya. European Journal of Neuroscience, 2007, 25, 2009-2020.	1.2	50
170	Cluster headache and the hypocretin receptor 2 reconsidered: A genetic association study and meta-analysis. Cephalalgia, 2015, 35, 741-747.	1.8	50
171	The anterior hypothalamus in cluster headache. Cephalalgia, 2017, 37, 1039-1050.	1.8	50
172	Lack of asymmetry of middle cerebral artery blood velocity in unilateral migraine.. Stroke, 1993, 24, 1335-1338.	1.0	49
173	Treatment effects and comorbid diseases in 58 patients with visual snow. Neurology, 2019, 93, e398-e403.	1.5	49
174	A genome-wide cross-phenotype meta-analysis of the association of blood pressure with migraine. Nature Communications, 2020, 11, 3368.	5.8	49
175	A review of the genetic relation between migraine and epilepsy. Cephalalgia, 2008, 28, 105-13.	1.8	49
176	Metabolic Profiling of Ultrasmall Sample Volumes with GC/MS: From Microliter to Nanoliter Samples. Analytical Chemistry, 2010, 82, 156-162.	3.2	48
177	What Do Patients Consider to Be the Most Important Outcomes for Effectiveness Studies on Migraine Treatment? Results of a Delphi Study. PLoS ONE, 2014, 9, e98933.	1.1	48
178	Interictal cortical hyperexcitability in migraine patients demonstrated with transcranial magnetic stimulation. Journal of the Neurological Sciences, 1996, 139, 106-10.	0.3	48
179	Familial hemiplegic migraine in the Netherlands. Clinical Neurology and Neurosurgery, 1994, 96, 244-249.	0.6	47
180	Migraine in the Triptan Era: Lessons From Epidemiology, Pathophysiology, and Clinical Science. Headache, 2009, 49, S21-33.	1.8	47

#	Article	IF	Citations
181	A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. Journal of Headache and Pain, 2011, 12, 361-368.	2.5	47
182	Cluster headache and depression. Neurology, 2016, 87, 1899-1906.	1.5	47
183	Gene-based pleiotropy across migraine with aura and migraine without aura patient groups. Cephalalgia, 2016, 36, 648-657.	1.8	47
184	Gene co-expression analysis identifies brain regions and cell types involved in migraine pathophysiology: a GWAS-based study using the Allen Human Brain Atlas. Human Genetics, 2016, 135, 425-439.	1.8	47
185	311C90: Increasing the options for therapy with effective acute antimigraine 5HT _{1B/1D} receptor agonists. Neurology, 1997, 48, S21-4.	1.5	46
186	Cluster headache in women: relation with menstruation, use of oral contraceptives, pregnancy, and menopause. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 690-692.	0.9	46
187	Cerebrovascular Reactivity Is a Main Determinant of White Matter Hyperintensity Progression in CADASIL. American Journal of Neuroradiology, 2009, 30, 1244-1247.	1.2	46
188	From Serotonin Receptor Classification to the Antimigraine Drug Sumatriptan. Cephalalgia, 1992, 12, 187-196.	1.8	45
189	Gene dosage-dependent transmitter release changes at neuromuscular synapses of Cacna1a R192Q knockin mice are non-progressive and do not lead to morphological changes or muscle weakness. Neuroscience, 2005, 135, 81-95.	1.1	45
190	Syncope and orthostatic intolerance increase risk of brain lesions in migraineurs and controls. Neurology, 2013, 80, 1958-1965.	1.5	45
191	Synaptic Gain-of-Function Effects of Mutant Ca_v2.1 Channels in a Mouse Model of Familial Hemiplegic Migraine Are Due to Increased Basal [Ca²⁺]_i. Journal of Neuroscience, 2014, 34, 7047-7058.	1.7	45
192	Plasma Interleukin-1, Tumour Necrosis Factor and Hypothalamic-Pituitary-Adrenal Axis Responses During Migraine Attacks. Cephalalgia, 1991, 11, 65-67.	1.8	44
193	Sumatriptan - Nonresponders: A Survey in 366 Migraine Patients. Headache, 1996, 36, 471-475.	1.8	44
194	Ophthalmoplegic Migraine: Migrainous or Inflammatory?. Cephalalgia, 2004, 24, 312-315.	1.8	44
195	Metabolic profiling of mouse cerebrospinal fluid by sheathless CE-MS. Analytical and Bioanalytical Chemistry, 2012, 404, 2895-2900.	1.9	44
196	Volumetric brain changes in migraineurs from the general population. Neurology, 2017, 89, 2066-2074.	1.5	44
197	Female sex hormones in men with migraine. Neurology, 2018, 91, e374-e381.	1.5	44
198	TREX1 gene variant in neuropsychiatric systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2010, 69, 1886-1887.	0.5	43

#	Article	IF	Citations
199	7â€˜T MRI reveals diffuse iron deposition in putamen and caudate nucleus in CADASIL. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1180-1185.	0.9	43
200	Biallelic mutations in neurofascin cause neurodevelopmental impairment and peripheral demyelination. Brain, 2019, 142, 2948-2964.	3.7	43
201	Bromocriptineâ€induced trigeminal patient with a neuralgia attacks in a pituitary tumor. Neurology, 1988, 38, 1482-1482.	1.5	43
202	No Involvement of the Calcium Channel Gene (CACNA1A) in a Family with Cluster Headache. Cephalalgia, 2001, 21, 959-962.	1.8	42
203	Large-scale plasma metabolome analysis reveals alterations in HDL metabolism in migraine. Neurology, 2019, 92, e1899-e1911.	1.5	42
204	Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane. British Journal of Pharmacology, 1996, 119, 855-862.	2.7	41
205	Within-patient consistency of response of rizatriptan for treating migraine. Neurology, 2000, 55, 1511-1516.	1.5	41
206	Systematic re-evaluation of genes from candidate gene association studies in migraine using a large genome-wide association data set. Cephalalgia, 2016, 36, 604-614.	1.8	41
207	Quantifying visual allodynia across migraine subtypes: the Leiden Visual Sensitivity Scale. Pain, 2018, 159, 2375-2382.	2.0	41
208	Involvement of a Ca 2+ Channel Gene in Familial Hemiplegic Migraine and Migraine With and Without Aura. Headache, 1997, 37, 479-485.	1.8	40
209	Genetic Biomarkers for Migraine. Headache, 2006, 46, 1059-1068.	1.8	39
210	Postdural puncture headache in migraineurs and nonheadache subjects. Neurology, 2013, 80, 941-948.	1.5	39
211	Abnormal synaptic <scp>C</scp>a²⁺ homeostasis and morphology in cortical neurons of familial hemiplegic migraine type 1 mutant mice. Annals of Neurology, 2015, 78, 193-210.	2.8	39
212	Reduced trigeminovascular cyclicity in patients with menstrually related migraine. Neurology, 2015, 84, 125-131.	1.5	39
213	Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response*. Clinical Pharmacology and Therapeutics, 1996, 60, 452-460.	2.3	38
214	Incipient CADASIL. Archives of Neurology, 2003, 60, 707.	4.9	38
215	Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy: Progression of MR Abnormalities in Prospective 7-year Follow-up Study. Radiology, 2008, 249, 964-971.	3.6	38
216	Antimigraine Efficacy of Telcagepant Based on Patient's Historical Triptan Response. Headache, 2011, 51, 64-72.	1.8	38

#	Article	IF	Citations
217	Pearls and pitfalls in genetic studies of migraine. Cephalalgia, 2013, 33, 614-625.	1.8	38
218	Migraine Prophylaxis, Ischemic Depolarizations, and Stroke Outcomes in Mice. Stroke, 2015, 46, 229-236.	1.0	38
219	Chronic Daily Headache in Children and Adolescents. Headache, 2005, 45, 678-683.	1.8	37
220	A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. Journal of Headache and Pain, 2011, 12, 219-226.	2.5	37
221	PRRT2 and hemiplegic migraine: A complex association. Neurology, 2014, 83, 288-290.	1.5	37
222	Plasma metabolic profiling after cortical spreading depression in a transgenic mouse model of hemiplegic migraine by capillary electrophoresis â€“ mass spectrometry. Molecular BioSystems, 2015, 11, 1462-1471.	2.9	37
223	Cortical Spreading Depression Causes Unique Dysregulation of Inflammatory Pathways in a Transgenic Mouse Model of Migraine. Molecular Neurobiology, 2017, 54, 2986-2996.	1.9	37
224	PARKINSONISM, TARDIVE DYSKINESIA, AKATHISIA, AND DEPRESSION INDUCED BY FLUNARIZINE. Lancet, The, 1986, 328, 292.	6.3	36
225	MRI findings in migraine. Revue Neurologique, 2005, 161, 661-665.	0.6	36
226	Detoxification in medication-overuse headache, a retrospective controlled follow-up study: Does care by a headache nurse lead to cure?. Cephalalgia, 2016, 36, 122-130.	1.8	36
227	Migraine and vascular disease biomarkers: A population-based case-control study. Cephalalgia, 2018, 38, 511-518.	1.8	36
228	The cardiovascular risk profile of middleâ€aged women with polycystic ovary syndrome. Clinical Endocrinology, 2020, 92, 150-158.	1.2	36
229	Imaging mass spectrometry to visualize biomolecule distributions in mouse brain tissue following hemispheric cortical spreading depression. Journal of Proteomics, 2012, 75, 5027-5035.	1.2	35
230	The comorbid relationship between migraine and epilepsy: a systematic review and metaâ€analysis. European Journal of Neurology, 2015, 22, 1038-1047.	1.7	35
231	Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis. Cephalalgia, 2019, 39, 967-977.	1.8	35
232	Cardiovascular risk prediction models for women in the general population: A systematic review. PLoS ONE, 2019, 14, e0210329.	1.1	35
233	Pharmacotherapy for Cluster Headache. CNS Drugs, 2020, 34, 171-184.	2.7	35
234	Treatment of Migraine Attacks with Subcutaneous Sumatriptan: First Placebo-Controlled Study. Cephalalgia, 1992, 12, 308-313.	1.8	34

#	Article	IF	Citations
235	Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology, 1995, 45, 1505-1509.	1.5	34
236	Episodic ataxia type 2. Journal of Neurology, 2002, 249, 1515-1519.	1.8	34
237	Is stress a trigger factor for migraine?. Psychoneuroendocrinology, 2007, 32, 532-538.	1.3	34
238	Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study. Neurological Sciences, 2010, 31, 51-54.	0.9	34
239	Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan. Journal of Headache and Pain, 2011, 12, 609-615.	2.5	34
240	Migraine Mutations Impair Hippocampal Learning Despite Enhanced Long-Term Potentiation. Journal of Neuroscience, 2015, 35, 3397-3402.	1.7	34
241	Cross-trait analyses with migraine reveal widespread pleiotropy and suggest a vascular component to migraine headache. International Journal of Epidemiology, 2020, 49, 1022-1031.	0.9	34
242	A four-generation Dutch family with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), linked to chromosome 19p13. Clinical Neurology and Neurosurgery, 1995, 97, 307-313.	0.6	33
243	Verapamil induced gingival enlargement in cluster headache. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 124-127.	0.9	33
244	Enhanced circadian phase resetting in R192Q Ca_v2.1 calcium channel migraine mice. Annals of Neurology, 2008, 64, 315-324.	2.8	33
245	Gain of Function in FHM-1 Cav2.1 Knock-In Mice Is Related to the Shape of the Action Potential. Journal of Neurophysiology, 2010, 104, 291-299.	0.9	33
246	Symptom dimensions of affective disorders in migraine patients. Journal of Psychosomatic Research, 2015, 79, 458-463.	1.2	33
247	Migraine and Cerebrovascular Atherosclerosis in Patients With Ischemic Stroke. Stroke, 2017, 48, 1973-1975.	1.0	33
248	Quantitative profiling of endocannabinoids and related N-acylethanolamines in human CSF using nano LC-MS/MS. Journal of Lipid Research, 2017, 58, 615-624.	2.0	33
249	Alternating Hemiplegia of Childhood: No Mutations in the Familial Hemiplegic Migraine CACNA1A Gene. Cephalalgia, 2000, 20, 696-700.	1.8	32
250	How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians. Current Medical Research and Opinion, 2005, 21, 413-424.	0.9	32
251	T₁ relaxation in in vivo mouse brain at ultraâ€high field. Magnetic Resonance in Medicine, 2007, 58, 390-395.	1.9	32
252	Reduced Sleep and Low Adenosinergic Sensitivity in Cacna1a R192Q Mutant Mice. Sleep, 2013, 36, 127-136.	0.6	32

#	Article	IF	Citations
253	Allodynia is associated with a higher prevalence of depression in migraine patients. Cephalalgia, 2014, 34, 1187-1192.	1.8	32
254	Concordance of genetic risk across migraine subgroups: Impact on current and future genetic association studies. Cephalalgia, 2015, 35, 489-499.	1.8	32
255	Should We Advise Patients to Treat Migraine Attacks Early?. Cephalalgia, 2004, 24, 915-927.	1.8	31
256	The impact of a migraine attack and its after-effects on perceptual organization, attention, and working memory. Cephalalgia, 2011, 31, 1419-1427.	1.8	31
257	Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. Journal of Headache and Pain, 2012, 13, 401-406.	2.5	31
258	The Mechanism of Functional Up-Regulation of P2X3 Receptors of Trigeminal Sensory Neurons in a Genetic Mouse Model of Familial Hemiplegic Migraine Type 1 (FHM-1). PLoS ONE, 2013, 8, e60677.	1.1	31
259	Clinical effects and mechanism of action of sumatriptan in migraine. Clinical Neurology and Neurosurgery, 1992, 94, 73-77.	0.6	30
260	Ischemic and hemorrhagic stroke in patients on oral anticoagulants after reconstruction for chronic lower limb ischemia.. Stroke, 1993, 24, 1655-1663.	1.0	30
261	Alternating Hemiplegia of Childhood: No Mutations in the Second Familial Hemiplegic Migraine GeneATP1A2. Neuropediatrics, 2004, 35, 293-296.	0.3	30
262	Evaluating the IHS Criteria for Cluster Headache â€“ a Comparison between Patients Meeting all Criteria and Patients Failing One Criterion. Cephalalgia, 2006, 26, 241-245.	1.8	30
263	Conditional inactivation of theCacna1a gene in transgenic mice. Genesis, 2006, 44, 589-594.	0.8	30
264	Predictors of Migraine Headache Recurrence: A Pooled Analysis From the Eletriptan Database. Headache, 2007, 48, 070629211050002-???.	1.8	30
265	Chapter 3 Familial Hemiplegic Migraine. Advances in Genetics, 2008, 63, 57-83.	0.8	30
266	Lenticulostriate Arterial Lumina Are Normal in Cerebral Autosomal-Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. Stroke, 2010, 41, 2812-2816.	1.0	30
267	Immunohistochemical characterization of calcitonin gene-related peptide in the trigeminal system of the familial hemiplegic migraine 1 knock-in mouse. Cephalalgia, 2011, 31, 1368-1380.	1.8	30
268	Spreading depolarizations increase delayed brain injury in a rat model of subarachnoid hemorrhage. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1224-1231.	2.4	30
269	Linking migraine frequency with family history of migraine. Cephalalgia, 2019, 39, 229-236.	1.8	30
270	Calcium channel mutations and migraine. Current Opinion in Neurology, 2002, 15, 311-316.	1.8	29

#	Article	IF	Citations
271	The biological clock in cluster headache: A review and hypothesis. Cephalalgia, 2019, 39, 1855-1866.	1.8	29
272	Alcoholic beverages as trigger factor and the effect on alcohol consumption behavior in patients with migraine. European Journal of Neurology, 2019, 26, 588-595.	1.7	29
273	Systemic features of retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations: a monogenic small vessel disease. Journal of Internal Medicine, 2019, 285, 317-332.	2.7	29
274	Chromosomal localization of the 5-HT1F receptor gene: No evidence for involvement in response to sumatriptan in migraine patients. American Journal of Medical Genetics Part A, 1998, 77, 415-420.	2.4	28
275	Impairment of Trigeminal Sensory Pathways in Cluster Headache. Cephalalgia, 2003, 23, 414-419.	1.8	28
276	Single-fiber EMG in familial hemiplegic migraine. Neurology, 2004, 63, 1942-1943.	1.5	28
277	Space Headache: A New Secondary Headache. Cephalalgia, 2009, 29, 683-686.	1.8	28
278	A novel SLC2A1 mutation linking hemiplegic migraine with alternating hemiplegia of childhood. Cephalalgia, 2015, 35, 10-15.	1.8	28
279	Recurrent coma and fever in familial hemiplegic migraine type 2. A prospective 15-year follow-up of a large family with a novel ATP1A2 mutation. Cephalalgia, 2017, 37, 737-755.	1.8	28
280	Migraine polygenic risk score associates with efficacy of migraine-specific drugs. Neurology: Genetics, 2019, 5, e364.	0.9	28
281	Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial. Lancet Neurology, The, 2021, 20, 515-525.	4.9	28
282	Familial Cyclic Vomiting Syndrome. Cephalalgia, 2002, 22, 552-554.	1.8	27
283	Understanding migraine using dynamic network biomarkers. Cephalalgia, 2015, 35, 627-630.	1.8	27
284	Large-Scale Mass Spectrometry Imaging Investigation of Consequences of Cortical Spreading Depression in a Transgenic Mouse Model of Migraine. Journal of the American Society for Mass Spectrometry, 2015, 26, 853-861.	1.2	27
285	Stress hormone corticosterone enhances susceptibility to cortical spreading depression in familial hemiplegic migraine type 1 mutant mice. Experimental Neurology, 2015, 263, 214-220.	2.0	27
286	Familial hemiplegic migraine is associated with febrile seizures in an FHM2 family with a novel de novo ATP1A2 mutation. Epilepsia, 2009, 50, 2503-2504.	2.6	26
287	Cerebral perfusion changes in migraineurs: a voxelwise comparison of interictal dynamic susceptibility contrast MRI measurements. Cephalalgia, 2012, 32, 279-288.	1.8	26
288	Two novel SCN1A mutations identified in families with familial hemiplegic migraine. Cephalalgia, 2014, 34, 1062-1069.	1.8	26

#	Article	IF	Citations
289	Efficacy of ICS 205-930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks. A complex answer to a simple question. Pain, 1991, 45, 283-291.	2.0	25
290	5-HT3 receptor antagonists and migraine therapy. Journal of Neurology, 1991, 238, S53-S56.	1.8	25
291	Auditory Evoked Potentials in the Assessment of Central Nervous System Effects of Antimigraine Drugs. Cephalalgia, 1999, 19, 880-885.	1.8	25
292	Compensatory Contribution of Cav2.3 Channels to Acetylcholine Release at the Neuromuscular Junction of Tottering Mice. Journal of Neurophysiology, 2006, 95, 2698-2704.	0.9	25
293	Characterization of acetylcholine release and the compensatory contribution of non-Cav2.1 channels at motor nerve terminals of leaner Cav2.1-mutant mice. Neuroscience, 2007, 144, 1278-1287.	1.1	25
294	Stepwise web-based questionnaires for diagnosing cluster headache: LUCA and QATCH. Cephalalgia, 2013, 33, 924-931.	1.8	25
295	Restless legs syndrome in migraine patients: prevalence and severity. European Journal of Neurology, 2016, 23, 1110-1116.	1.7	25
296	Long-term Efficacy and Safety of Erenumab. Neurology, 2021, 96, .	1.5	25
297	The 3p21.1-p21.3 Hereditary Vascular Retinopathy Locus Increases the Risk for Raynaud's Phenomenon and Migraine. Cephalalgia, 2005, 25, 1168-1172.	1.8	24
298	Premature stop codons in a facilitating EF-hand splice variant of CaV2.1 cause episodic ataxia type 2. Neurobiology of Disease, 2008, 32, 10-15.	2.1	24
299	Genetics of migraine: an update with special attention to genetic comorbidity. Current Opinion in Neurology, 2008, 21, 288-293.	1.8	24
300	Severe and Progressive Neurotransmitter Release Aberrations in Familial Hemiplegic Migraine Type 1 Cacna1a S218L Knock-in Mice. Journal of Neurophysiology, 2010, 104, 1445-1455.	0.9	24
301	Biochemical changes in the brain of hemiplegic migraine patients measured with 7 tesla ¹H-MRS. Cephalalgia, 2014, 34, 959-967.	1.8	24
302	Repeatability of the Intensity Dependence of Cortical Auditory Evoked Potentials in the Assessment of Cortical Information Processing. Cephalalgia, 1999, 19, 873-879.	1.8	23
303	The impact of pharmacogenetics for migraine. European Journal of Pharmacology, 2001, 413, 1-10.	1.7	23
304	TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management. Acta Neurologica Scandinavica, 2004, 110, 137-143.	1.0	23
305	A hyperexcitability phenotype in mouse trigeminal sensory neurons expressing the R192Q Cacna1a missense mutation of familial hemiplegic migraine type-1. Neuroscience, 2014, 266, 244-254.	1.1	23
306	Microfabricated solid-state ion-selective electrode probe for measuring potassium in the living rodent brain: Compatibility with DC-EEG recordings to study spreading depression. Sensors and Actuators B: Chemical, 2015, 207, 945-953.	4.0	23

#	Article	IF	Citations
307	RVCL-S and CADASIL display distinct impaired vascular function. Neurology, 2018, 91, e956-e963.	1.5	23
308	The use of multiattribute decision models in evaluating triptan treatment options in migraine. Journal of Neurology, 2005, 252, 1026-1032.	1.8	22
309	Genetics of headaches. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 85-97.	1.0	22
310	Migraine Strikes as Neuronal Excitability Reaches a Tipping Point. PLoS ONE, 2013, 8, e72514.	1.1	22
311	Familial hemiplegic migraine treated by sodium valproate and lamotrigine. Cephalalgia, 2014, 34, 708-711.	1.8	22
312	Cerebellar function and ischemic brain lesions in migraine patients from the general population. Cephalalgia, 2017, 37, 177-190.	1.8	22
313	Allodynia in cluster headache. Pain, 2017, 158, 1113-1117.	2.0	22
314	Genetic Susceptibility Loci in Genomewide Association Study of Cluster Headache. Annals of Neurology, 2021, 90, 203-216.	2.8	22
315	Blood Flow Velocities in the Vertebrobasilar System During Migraine Attacks a Transcranial Doppler Study. Cephalalgia, 1992, 12, 29-32.	1.8	21
316	Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks. British Journal of Clinical Pharmacology, 1999, 47, 285-290.	1.1	21
317	Human Isolated Coronary Artery Contraction To Sumatriptan: A Post Hoc Analysis. Cephalalgia, 1999, 19, 651-654.	1.8	21
318	The efficacy and safety of sc Alniditan vs. sc Sumatriptan in the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial. Cephalalgia, 2001, 21, 672-679.	1.8	21
319	Chronic cluster headache: a review. Journal of Headache and Pain, 2005, 6, 3-9.	2.5	21
320	Quantitative cortical synapse proteomics of a transgenic migraine mouse model with mutated Ca_V2.1 calcium channels. Proteomics, 2010, 10, 2531-2535.	1.3	21
321	Prophylactic treatment of migraine; the patient's view, a qualitative study. BMC Family Practice, 2012, 13, 13.	2.9	21
322	Presynaptic Ca_V2.1 calcium channels carrying familial hemiplegic migraine mutation R192Q allow faster recovery from synaptic depression in mouse calyx of Held. Journal of Neurophysiology, 2012, 108, 2967-2976.	0.9	21
323	Differential trigeminovascular nociceptive responses in the thalamus in the familial hemiplegic migraine 1 knock-in mouse: A Fos protein study. Neurobiology of Disease, 2014, 64, 1-7.	2.1	21
324	Evaluation of the new ICHD-III beta cluster headache criteria. Cephalalgia, 2016, 36, 547-551.	1.8	21

#	Article	IF	Citations
325	Increased use of illicit drugs in a Dutch cluster headache population. Cephalalgia, 2019, 39, 626-634.	1.8	21
326	Headache in people with epilepsy. Nature Reviews Neurology, 2021, 17, 529-544.	4.9	21
327	First case of compound heterozygosity in Na,K-ATPase gene ATP1A2 in familial hemiplegic migraine. European Journal of Human Genetics, 2007, 15, 884-888.	1.4	20
328	CACNA1A R1347Q: a frequent recurrent mutation in hemiplegic migraine. Clinical Genetics, 2008, 74, 481-485.	1.0	20
329	Preventive treatment for migraine in primary care, a population-based study in the Netherlands. Cephalalgia, 2013, 33, 1170-1178.	1.8	20
330	Candidate-gene association study searching for genetic factors involved in migraine chronification. Cephalalgia, 2015, 35, 500-507.	1.8	20
331	Identifying a gene expression signature of cluster headache in blood. Scientific Reports, 2017, 7, 40218.	1.6	20
332	Release of platelet Met-enkephalin, but not serotonin, in migraine. Journal of the Neurological Sciences, 1989, 93, 51-60.	0.3	19
333	Intracellular and Plasma Magnesium in Familial Hemiplegic Migraine and Migraine With and Without Aura. Cephalalgia, 1994, 14, 29-32.	1.8	19
334	The Factor V Leiden Mutation (R506Q) is not a Major Risk Factor for Migrainous Cerebral Infarction. Cephalalgia, 1997, 17, 605-607.	1.8	19
335	Voxel-Based Morphometry in Hypocretin-Deficient Narcolepsy. Sleep, 2003, , .	0.6	19
336	Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR project). Clinical Therapeutics, 2004, 26, 1533-1545.	1.1	19
337	Brain atrophy following hemiplegic migraine attacks. Cephalalgia, 2018, 38, 1199-1202.	1.8	19
338	Chronobiology and Sleep in Cluster Headache. Headache, 2019, 59, 1032-1041.	1.8	19
339	Assessment of Peripheral Vascular Effects of Antimigraine Drugs in Humans. Cephalalgia, 1995, 15, 288-291.	1.8	18
340	Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. Clinical and Experimental Hypertension, 2006, 28, 271-277.	0.5	18
341	Coronary artery calcification in middleâ€aged women with premature ovarian insufficiency. Clinical Endocrinology, 2019, 91, 314-322.	1.2	18
342	Habitual sleep disturbances and migraine: a Mendelian randomization study. Annals of Clinical and Translational Neurology, 2020, 7, 2370-2380.	1.7	18

#	Article	IF	Citations
343	Migraine prevalence in visual snow with prior illicit drug use (hallucinogen persisting perception) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.7	18
344	Genetics of primary headaches. Current Opinion in Neurology, 1999, 12, 249-254.	1.8	18
345	The Clinical Effectiveness of 311C90 in the Acute Treatment of Migraine. European Neurology, 1996, 36, 4-7.	0.6	17
346	Monthly Update: Central & Peripheral Nervous Systems: Pharmacology of antimigraine 5-HT_{1D}receptor agonists. Expert Opinion on Investigational Drugs, 1996, 5, 581-593.	1.9	17
347	Mahler's Migraine. Cephalalgia, 2000, 20, 254-254.	1.8	17
348	Should We Advise Patients to Treat Migraine Attacks Early: Methodologic Issues. European Neurology, 2005, 53, 17-21.	0.6	17
349	Efficacy of frovatriptan versus other triptans in the acute treatment of menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies. Neurological Sciences, 2012, 33, 65-69.	0.9	17
350	Premonitory symptoms in glyceryl trinitrate triggered migraine attacks: a case-control study. Pain, 2020, 161, 2058-2067.	2.0	17
351	A long-term follow-up study of 18 patients with sporadic hemiplegic migraine. Cephalalgia, 2011, 31, 199-205.	1.8	16
352	Clusterâ€Tic Syndrome: A Crossâ€Sectional Study of Cluster Headache Patients. Headache, 2013, 53, 1334-1340.	1.8	16
353	Systemic right-to-left shunts, ischemic brain lesions, and persistent migraine activity. Neurology, 2016, 86, 1668-1675.	1.5	16
354	Prioritizing treatment attributes and their impact on selecting an oral triptan: Results from the TRIPSTAR project. Current Pain and Headache Reports, 2004, 8, 435-442.	1.3	15
355	Alternating Hemiplegia of Childhood: No Mutations in the Glutamate Transporter EAAT1. Neuropediatrics, 2006, 37, 302-304.	0.3	15
356	The Phe-124-Cys and A-161T Variants of the Human 5-HT1BReceptor Gene Are Not Major Determinants of the Clinical Response to Sumatriptan. Headache, 2007, 47, 711-716.	1.8	15
357	Recurrent ATP1A2 mutations in Portuguese families with familial hemiplegic migraine. Journal of Human Genetics, 2007, 52, 990-998.	1.1	15
358	A proactive approach to migraine in primary care: a pragmatic randomized controlled trial. Cmaj, 2012, 184, E224-E231.	0.9	15
359	Genome wide association study identifies variants in NBEA associated with migraine in bipolar disorder. Journal of Affective Disorders, 2015, 172, 453-461.	2.0	15
360	Space headache on Earth: Head-down-tilted bed rest studies simulating outer-space microgravity. Cephalalgia, 2015, 35, 335-343.	1.8	15

#	Article	IF	Citations
361	Prevalence of lifetime depression in a large hemiplegic migraine cohort. Neurology, 2016, 87, 2370-2374.	1.5	15
362	Involvement of astrocyte and oligodendrocyte gene sets in migraine. Cephalalgia, 2016, 36, 640-647.	1.8	15
363	Iron in deep brain nuclei in migraine? CAMERA follow-up MRI findings. Cephalalgia, 2017, 37, 795-800.	1.8	15
364	Valproate Reduces Delayed Brain Injury in a Rat Model of Subarachnoid Hemorrhage. Stroke, 2017, 48, 452-458.	1.0	15
365	Microstructural white matter changes preceding white matter hyperintensities in migraine. Neurology, 2019, 93, e688-e694.	1.5	15
366	Acute treatment of migraine attacks. Current Opinion in Neurology, 1995, 8, 237-242.	1.8	14
367	Bovine isolated middle cerebral artery contractions to antimigraine drugs. Naunyn-Schmiedeberg's Archives of Pharmacology, 1999, 360, 591-596.	1.4	14
368	Typical Cluster Headache Caused by Granulomatous Pituitary Involvement. Cephalalgia, 2007, 27, 173-176.	1.8	14
369	Reduced ACh release at neuromuscular synapses of heterozygous leaner Ca_v2.1â€mutant mice. Synapse, 2008, 62, 337-344.	0.6	14
370	Migraine Genetics: A Fascinating Journey Towards Improved Migraine Therapy. Headache, 2008, 48, 697-700.	1.8	14
371	Cardiac monitoring of high-dose verapamil in cluster headache: An international Delphi study. Cephalalgia, 2016, 36, 1385-1388.	1.8	14
372	Aura in Cluster Headache: A Crossâ€Sectional Study. Headache, 2018, 58, 1203-1210.	1.8	14
373	MRI evaluation of the relationship between carotid artery endothelial shear stress and brain white matter lesions in migraine. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1040-1047.	2.4	14
374	Methionine-Enkephalin in Migraine and Tension Headache. Differences Between Classic Migraine, Common Migraine and Tension Headache, and Changes During Attacks.. Headache, 1990, 30, 160-164.	1.8	13
375	The Influence of Ergotamine Abuse on Psychological and Cognitive Functioning. Cephalalgia, 2000, 20, 462-469.	1.8	13
376	Cardiovascular Autonomic Function Tests in Cluster Headache. Cephalalgia, 2006, 26, 329-331.	1.8	13
377	Prophylactic treatment of migraine by GPs: a qualitative study. British Journal of General Practice, 2012, 62, e268-e274.	0.7	13
378	Infratentorial Microbleeds. Stroke, 2015, 46, 1987-1989.	1.0	13

#	Article	IF	Citations
379	Circulating Endothelial Markers in Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations. Stroke, 2017, 48, 3301-3307.	1.0	13
380	Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2â€“4 preventives were not useful: results from the LIBERTY study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 466-472.	0.9	13
381	Dopamine D2â€“Receptor Imaging With 123I-Iodobenzamide SPECT in Migraine Patients Abusing Ergotamine: Does Ergotamine Cross The Blood Brain Barrier?. Cephalalgia, 1993, 13, 325-329.	1.8	12
382	Sunct Syndrome Resolving After Contralateral Hemispheric Ischaemic Stroke. Cephalalgia, 2003, 23, 235-237.	1.8	12
383	Epilepsy in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. Cerebrovascular Diseases, 2007, 24, 316-317.	0.8	12
384	Redundancy of Cav2.1 channel accessory subunits in transmitter release at the mouse neuromuscular junction. Brain Research, 2007, 1143, 92-101.	1.1	12
385	Heterozygous TREX1 mutations in early-onset cerebrovascular disease. Journal of Neurology, 2013, 260, 2188-2190.	1.8	12
386	Ethanol contamination of cerebrospinal fluid during standardized sampling and its effect on 1H-NMR metabolomics. Analytical and Bioanalytical Chemistry, 2015, 407, 4835-4839.	1.9	12
387	Role of atherosclerosis, clot extent, and penumbra volume in headache during ischemic stroke. Neurology, 2016, 87, 1124-1130.	1.5	12
388	Relief Following Chronic Stress Augments Spreading Depolarization Susceptibility in Familial Hemiplegic Migraine Mice. Neuroscience, 2019, 415, 1-9.	1.1	12
389	Migraine Aura, Illusory Vertical Splitting, and Picasso. Cephalalgia, 2000, 20, 686-686.	1.8	11
390	A human capsaicin model to quantitatively assess salivary CGRP secretion. Cephalalgia, 2015, 35, 675-682.	1.8	11
391	NOn-invasive Vagus nerve stimulation in acute Ischemic Stroke (NOVIS): a study protocol for a randomized clinical trial. Trials, 2020, 21, 878.	0.7	11
392	Migraine as a Cerebral Ionopathy with Impaired Central Sensory Processing. , 2007, , 439-461.		11
393	Rapid Prototyping of Organ-on-a-Chip Devices Using Maskless Photolithography. Micromachines, 2022, 13, 49.	1.4	11
394	Effects of tertatolol, a Î²-adrenoceptor antagonist with agonist affinity at 5-HT1A receptors, in an animal model of migraine: comparison with propranolol and pindolol. European Journal of Pharmacology, 1992, 220, 79-86.	1.7	10
395	Toward a molecular genetic classification of familial hemiplegic migraine. Current Pain and Headache Reports, 2004, 8, 238-243.	1.3	10
396	Aortic root pathology in Marfan syndrome increases the risk of migraine with aura. Cephalalgia, 2012, 32, 467-472.	1.8	10

#	Article	IF	Citations
397	Headache: the changing migraine brain. Lancet Neurology, The, 2013, 12, 6-8.	4.9	10
398	Metabolomic changes in CSF of migraine patients measured with ¹H-NMR spectroscopy. Molecular BioSystems, 2016, 12, 3674-3682.	2.9	10
399	An n-of-one RCT for intravenous immunoglobulin G for inflammation in hereditary neuropathy with liability to pressure palsy (HNPP). Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 790-791.	0.9	10
400	Tumefactive lesions in retinal vasculopathy with cerebral leucoencephalopathy and systemic manifestations (RVCL-S): a role for neuroinflammation?. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 434-435.	0.9	10
401	Genetic factors in cluster headache. Expert Review of Neurotherapeutics, 2003, 3, 301-306.	1.4	9
402	Concomitant Headache Influences Long-term Prognosis After Acute Cerebral Ischemia of Noncardioembolic Origin. Stroke, 2013, 44, 2446-2450.	1.0	9
403	RNA expression profiling in brains of familial hemiplegic migraine type 1 knock-in mice. Cephalalgia, 2014, 34, 174-182.	1.8	9
404	Stroke progression and clinical outcome in ischemic stroke patients with a history of migraine. International Journal of Stroke, 2019, 14, 946-955.	2.9	9
405	Phase clustering in transcranial magnetic stimulation-evoked EEG responses in genetic generalized epilepsy and migraine. Epilepsy and Behavior, 2019, 93, 102-112.	0.9	9
406	Hypothalamic functional MRI activity in the initiation phase of spontaneous and glyceryl trinitrateâ€induced migraine attacks. European Journal of Neuroscience, 2021, 54, 5189-5202.	1.2	9
407	Tripstar: A Comprehensive Patient-Based Approach to Compare Triptans. Headache, 2002, 42, 18-25.	1.8	8
408	Picassoâ€™s migraine: Illusory cubist splitting or illusion?. Cephalalgia, 2011, 31, 1057-1060.	1.8	8
409	Cardiovascular risk model performance in women with and without hypertensive disorders of pregnancy. Heart, 2019, 105, 330-336.	1.2	8
410	Responsivity to light in familial hemiplegic migraine type 1 mutant mice reveals frequencyâ€dependent enhancement of visual network excitability. European Journal of Neuroscience, 2021, 53, 1672-1686.	1.2	8
411	A Migrainous Syndrome with Pleocytosis. Neurology, 1983, 33, 813-813.	1.5	8
412	Characterization of virus infected cell cultures by pyrolysis/direct chemical ionization mass spectrometry. Biomedical & Environmental Mass Spectrometry, 1989, 18, 757-760.	1.6	7
413	The Transition G To A at Position 20210 in the 3'-Untranslated Region of the Prothrombin Gene is Not Associated with Migrainous Infarction. Cephalalgia, 1998, 18, 229-230.	1.8	7
414	Reproducibility and Feasibility of Neurophysiological Assessment of the Sensory Trigeminal System for Future Application To Paroxysmal Headaches. Cephalalgia, 2002, 22, 474-481.	1.8	7

#	Article	IF	Citations
415	Transmitter Release Deficits at the Neuromuscular Synapse of Mice with Mutations in the Cav2.1 (Î±1A) Subunit of the P/Q-Type Ca2+Channel. Annals of the New York Academy of Sciences, 2003, 998, 29-32.	1.8	7
416	Trigeminal autonomic cephalalgia-tic-like syndrome associated with a pontine tumour in a one year old girl. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 391-392.	0.9	7
417	Migraine and epilepsy: genetically linked?. Expert Review of Neurotherapeutics, 2008, 8, 1307-1311.	1.4	7
418	Strategies to assess and optimize stability of endogenous amines during cerebrospinal fluid sampling. Metabolomics, 2018, 14, 44.	1.4	7
419	Cortical glutamate and gamma-aminobutyric acid over the course of a provoked migraine attack, a 7 Tesla magnetic resonance spectroscopy study. NeuroImage: Clinical, 2021, 32, 102889.	1.4	7
420	Elucidating the relationship between migraine risk and brain structure using genetic data. Brain, 2022, 145, 3214-3224.	3.7	7
421	COVID-19 vaccination-triggered cluster headache episodes with frequent attacks. Cephalalgia, 2022, 42, 1420-1424.	1.8	7
422	The quest for migraine genes. Current Opinion in Neurology, 1997, 10, 221-225.	1.8	6
423	Familial hemiplegic migraine type-1 mutated cav2.1 calcium channels alter inhibitory and excitatory synaptic transmission in the lateral superior olive of mice. Hearing Research, 2015, 319, 56-68.	0.9	6
424	Circle of Willis variations in migraine patients with ischemic stroke. Brain and Behavior, 2019, 9, e01223.	1.0	6
425	Enhanced pre-ictal cortical responsivity in migraine patients assessed by visual chirp stimulation. Cephalalgia, 2020, 40, 913-923.	1.8	6
426	Transient Resolution of Headache in Giant Cell Temporal Arteritis After Sumatriptan. Cephalalgia, 1993, 13, 426-426.	1.8	5
427	Rizatriptan: A New Milestone in Migraine Treatment. Introduction. Cephalalgia, 2000, 20, 1-1.	1.8	5
428	Sumatriptan by Injection. Cephalalgia, 2001, 21, 6-8.	1.8	5
429	A Patient with Long-Lasting Attacks of Bilateral â€˜Blepharospasmâ€™, Photophobia, Lacrimation and Rhinorrhoea. Cephalalgia, 2004, 24, 143-146.	1.8	5
430	Anatomical Variations in the Circle of Willis and Migraine Susceptibility: Is There an Association?. Headache, 2010, 50, 151-152.	1.8	5
431	Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: a subgroup analysis of a double-blind, randomized, multicenter, Italian study. Neurological Sciences, 2012, 33, 61-64.	0.9	5
432	The cavernous sinus in cluster headache â€“ a quantitative structural magnetic resonance imaging study. Cephalalgia, 2017, 37, 208-213.	1.8	5

#	Article	IF	Citations
433	Repeated greater occipital nerve injections with corticosteroids in medically intractable chronic cluster headache: a retrospective study. Neurological Sciences, 2022, 43, 1267-1272.	0.9	5
434	The effect of needle size on cerebrospinal fluid collection time and postâ€dural puncture headache: A retrospective cohort study. Headache, 2021, 61, 329-334.	1.8	5
435	Migraine as a Cerebral Ionopathy with Abnormal Central Sensory Processing**Some portions of the pathophysiology have appeared fully referenced [1].. , 2007, , 333-348.		5
436	CaV2.1 channel mutations causing familial hemiplegic migraine type 1 increase the susceptibility for cortical spreading depolarizations and seizures and worsen outcome after experimental traumatic brain injury. ELife, 2022, 11, .	2.8	5
437	Chorea and Migraine: â€œHemicrania Choreaticaâ€?. Cephalalgia, 1984, 4, 119-124.	1.8	4
438	Intermittent pyramidal claudication as presenting and sole symptom in multiple sclerosis.. Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 147-148.	0.9	4
439	Emerging Preclinical and Clinical Profile of 311C90: A Poster Review and Discussion. European Neurology, 1996, 36, 19-23.	0.6	4
440	Search for mitochondrial DNA mutations in migraine subgroups. Cephalalgia, 1999, 19, 20-22.	1.8	4
441	Editorial Commentary. Cephalalgia, 2001, 21, 711-711.	1.8	4
442	No indication for patent foramen ovale closure in migraine. Netherlands Heart Journal, 2009, 17, 320-321.	0.3	4
443	An early 18th-century case description of cluster headache. Cephalalgia, 2010, 30, 1392-1395.	1.8	4
444	The adverse effects of antiepileptic drugs differ in patients with migraine. Lancet Neurology, The, 2012, 11, 935.	4.9	4
445	Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults. Cephalalgia, 2019, 39, 1058-1066.	1.8	4
446	The genetics of migraine: implication for treatment approaches. , 2002, , 111-127.		4
447	Sex Differences in Risk Profile, Stroke Cause and Outcome in Ischemic Stroke Patients With and Without Migraine. Frontiers in Neuroscience, 2021, 15, 740639.	1.4	4
448	Migraine: new treatment options from molecular biology. Expert Review of Neurotherapeutics, 2005, 5, 653-661.	1.4	3
449	A Gene for a New Monogenic Neurovascular Migraine Syndrome: A Next Step in Unravelling Molecular Pathways for Migraine?. Cephalalgia, 2008, 28, 471-473.	1.8	3
450	Reply to: Migraine headache is not associated with cerebral or meningeal vasodilatation--a 3T magnetic resonance angiography study. Brain, 2009, 132, e113-e113.	3.7	3

#	Article	IF	Citations
451	Time lost due to an attack â€“ a novel patient-reported outcome measure for acute migraine treatments. Cephalalgia, 2021, 41, 1027-1032.	1.8	3
452	No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: Results of two randomized, double-blind, placebo-controlled clinical trials. , 2000, 47, 238.		3
453	Genetics and pathology of voltage-gated Ca2+ channels. Histology and Histopathology, 1998, 13, 827-36.	0.5	3
454	Ergot Alkaloids Reduce Cranial Arteriovenous Shunting In Pigs: No Major Role for 5-Ht₁-Like Receptors. Cephalalgia, 1991, 11, 203-204.	1.8	2
455	Dihydroergotamine nasal spray. Neurology, 1995, 45, 397.	1.5	2
456	Nerve conduction sensitivity in diabetic neuropathy. , 1999, 22, 140-140.		2
457	Letters to the Editor. Headache, 2003, 43, 814-823.	1.8	2
458	A breathtaking headache. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 509-509.	0.9	2
459	Migraine as a Risk Factor for Subclinical Brain Lesionsâ€”Reply. JAMA - Journal of the American Medical Association, 2004, 291, 2072.	3.8	2
460	Hemiplegic and Basilar-type Migraine: Current and Future Treatment. Headache Currents: A Journal for Recent Advances in Headache and Facial Pain, 2006, 3, 97-100.	0.7	2
461	Primary headaches. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 267-284.	1.0	2
462	Abnormal cardiovascular response to nitroglycerin in migraine. Cephalalgia, 2020, 40, 266-277.	1.8	2
463	Reply: OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine. Brain, 2020, 143, e6-e6.	3.7	2
464	Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid. Headache, 2022, 62, 530-533.	1.8	2
465	George W. Bruyn, Born Delft, 14 December 1928, Died La Salvetat, 23 June 2002. Cephalalgia, 2002, 22, 767-768.	1.8	1
466	Reply: Impairment of Trigeminal Sensory Pathways in Cluster Headache. Cephalalgia, 2004, 24, 910-911.	1.8	1
467	Migraine as a Risk Factor for White Matter Lesions, Silent Infarctions, and Ischemic Stroke: The Evidence for a Link. Headache Currents: A Journal for Recent Advances in Headache and Facial Pain, 2005, 2, 62-70.	0.7	1
468	John Edmeads Celebration of a Life (April 15, 1936?November 16, 2006). Headache, 2007, 47, 160-168.	1.8	1

#	Article	IF	Citations
469	The Lancet and advertorials. Lancet, The, 2009, 373, 1004-1005.	6.3	1
470	Serotonin, NO, and CGRP and Headache. Headache, 2011, 51, 1046-1048.	1.8	1
471	Right-to-left shunts and micro-embolization in migraine. Current Opinion in Neurology, 2012, 25, 263-268.	1.8	1
472	Novel SCN1A mutation in the IFMT motif of the Î±1 subunit of the voltage-gated NaV1.1 channel causing familial hemiplegic migraine. Journal of Headache and Pain, 2013, 14, .	2.5	1
473	Frovatriptan vs other triptans in the treatment of menstrual migraine: pooled analysis of three double-blind, randomized, cross-over studies. Journal of Headache and Pain, 2013, 14, .	2.5	1
474	Spreading depolarization-modulating drugs and delayed cerebral ischemia after subarachnoid hemorrhage: A hypothesis-generating retrospective clinical study. Journal of the Neurological Sciences, 2016, 366, 224-228.	0.3	1
475	Unilateral increased visual sensitivity in cluster headache: a cross-sectional study. Cephalalgia, 2022, , 033310242210776.	1.8	1
476	Treating migraine attacks ASAP: concept and methodological issues. , 0, , 53-62.		0
477	Relief of common migraine by exercise.. Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 1011-1011.	0.9	0
478	Vascular Effects of Serotonin in Migraine Patients. Cephalalgia, 1989, 9, 86-87.	1.8	0
479	Effect of Sumatriptan on Cerebral Bloodflow During and Outside Migraine Attacks: A Tc-99M Hmpao Spect and Transcranial Doppler Study.. Cephalalgia, 1991, 11, 205-205.	1.8	0
480	Genetic biomarkers. Journal of Cellular Biochemistry, 1993, 53, 205-205.	1.2	0
481	CACNA1A gene mutations in familial hemiplegic migraine. Journal of Headache and Pain, 2000, 1, S121-S128.	2.5	0
482	Authors' Reply: Abdominal Migraine. Cephalalgia, 2003, 23, 242-242.	1.8	0
483	Treating Migraine Attacks ASAP: Concept and Methodological Issues. Progress in Neurotherapeutics and Neuropsychopharmacology, 2006, 1, 53-61.	0.0	0
484	Intractable Headache Criteria: Reply. Cephalalgia, 2007, 27, 859-859.	1.8	0
485	IN64-FR-01 From migraine genes to migraine triggering mechanisms and prophylaxis. Journal of the Neurological Sciences, 2009, 285, S46.	0.3	0
486	Retinal photography: A diagnostic tool for small vessel disease of the brain?. Journal of the Neurological Sciences, 2009, 283, 273.	0.3	0

#	Article	IF	Citations
487	Migraine and olcegepant â€“ Authors' reply. Lancet, The, 2009, 373, 1003-1004.	6.3	0
488	Migraine without aura: genome-wide association analysis identifies several novel susceptibility. Journal of Headache and Pain, 2013, 14, .	2.5	0
489	Migraine without aura: genome-wide association analysis identifies several novel susceptibility. Journal of Headache and Pain, 2013, 14, .	2.5	0
490	Frovatriptan vs almotriptan for treatment of menstrual migraine: a double-blind, randomized, cross-over, multicenter Italian study. Journal of Headache and Pain, 2013, 14, .	2.5	0
491	Postural sway in migraine patients and controls, results from a population based CAMERA-2 study. Journal of Headache and Pain, 2013, 14, .	2.5	0
492	Corticosterone enhances CSD susceptibility via glucocorticoid receptor activation in familial hemiplegic migraine 1 Cacna1a knock-in mice. Journal of Headache and Pain, 2013, 14, .	2.5	0
493	Monitoring cortical neuronal activity and spreading depression in freely behaving familial hemiplegic migraine Cacna1a R192Q knockin mice. Journal of Headache and Pain, 2013, 14, .	2.5	0
494	EHMTI-0262. Dysregulation of inflammatory pathways in a familial hemiplegic migraine 1 mouse model after the induction of cortical spreading depression. Journal of Headache and Pain, 2014, 15, .	2.5	0
495	Migraine with Aura: A CADASIL Case. Headache, 2015, , 53-58.	0.2	0
496	096â€…Assessment of the efficacy of erenumab during the open-label treatment (13â€“24 weeks) of subjects with episodic migraine who failed 2â€“4 prior preventive treatments: results of the LIBERTY study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A31.1-A31.	0.9	0
497	Reply. Pain, 2019, 160, 985-985.	2.0	0
498	Functional changes of vascular responses in familial hemiplegic migraine type 1. FASEB Journal, 2011, 25, .	0.2	0
499	Prothrombotic mutations and ischaemic stroke at a young age in two sisters. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 958-959.	0.9	0
500	Current perspectives on effective migraine treatments: are small clinical differences important for patients?. Drugs of Today, 2003, 39 Suppl D, 37-41.	0.7	0